The drug development process: from target discovery to the clinic

by Newell, David R
Published in Clin Med (Lond) (2003)

Pharmacological Biomarkers in the Development of Stratified Cancer Medicine

by Figg, William Douglas, Newell, David R.
Published 2014

Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2

by Vormoor, Britta, Schlosser, Yvonne T., Blair, Helen, Sharma, Abhishek, Wilkinson, Sarah, Newell, David R., Curtin, Nicola
Published in Oncotarget (2017)

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

by Chen, Lindi, Rousseau, Raphaël F., Middleton, Steven A., Nichols, Gwen L., Newell, David R., Lunec, John, Tweddle, Deborah A.
Published in Oncotarget (2015)

Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer

by Batey, Michael A, Zhao, Yan, Kyle, Suzanne, Richardson, Caroline, Slade, Andrew, Martin, Niall MB, Lau, Alan, Newell, David R, Curtin, Nicola J
Published 2013

The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [(18)F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice

by Haagensen, Emma J., Thomas, Huw D., Wilson, Ian, Harnor, Suzannah J., Payne, Sara L., Rennison, Tommy, Smith, Kate M., Maxwell, Ross J., Newell, David R.
Published 2013

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation

by Lochhead, Pamela A., Clark, Jonathan, Wang, Lan-Zhen, Gilmour, Lesley, Squires, Matthew, Gilley, Rebecca, Foxton, Caroline, Newell, David R., Wedge, Stephen R., Cook, Simon J.
Published in Cell Cycle (2016)

Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037

by Haagensen, Emma J., Thomas, Huw D., Schmalix, Wolfgang A., Payne, Andrew C., Kevorkian, Lara, Allen, Rodger A., Bevan, Paul, Maxwell, Ross J., Newell, David R.
Published in Cancer Chemother Pharmacol (2016)

Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide

by Thomas, Huw D, Porter, David J, Bartelink, Imke, Nobbs, Joy R, Cole, Michael, Elliott, Suzie, Newell, David R, Calvert, A Hilary, Highley, Martin, Boddy, Alan V
Published 2002

Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases

by Reuillon, Tristan, Alhasan, Sari F., Beale, Gary S., Bertoli, Annalisa, Brennan, Alfie, Cano, Celine, Reeves, Helen L., Newell, David R., Golding, Bernard T., Miller, Duncan C., Griffin, Roger J.
Published in Chem Sci (2016)

Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM

by Matheson, Elizabeth C., Thomas, Huw, Case, Marian, Blair, Helen, Jackson, Rosanna K., Masic, Dino, Veal, Gareth, Halsey, Chris, Newell, David R., Vormoor, Josef, Irving, Julie A.E.
Published in Haematologica (2019)

Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma

by Alhasan, Sari F, Haugk, Beate, Ogle, Laura F, Beale, Gary S, Long, Anna, Burt, Alastair D, Tiniakos, Dina, Televantou, Despina, Coxon, Fareeda, Newell, David R, Charnley, Richard, Reeves, Helen L
Published in Br J Cancer (2016)

Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer

by Beale, Gary, Haagensen, Emma J, Thomas, Huw D, Wang, Lan-Zhen, Revill, Charlotte H, Payne, Sara L, Golding, Bernard T, Hardcastle, Ian R, Newell, David R, Griffin, Roger J, Cano, Celine
Published in Br J Cancer (2016)

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

by Chen, Lindi, Pastorino, Fabio, Berry, Philip, Bonner, Jennifer, Kirk, Calum, Wood, Katrina M., Thomas, Huw D., Zhao, Yan, Daga, Antonio, Veal, Gareth J., Lunec, John, Newell, David R., Ponzoni, Mirco, Tweddle, Deborah A.
Published in Int J Cancer (2019)

Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2–p53 and MDMX–p53 protein–protein interactions

by Blackburn, Tim J., Ahmed, Shafiq, Coxon, Christopher R., Liu, Junfeng, Lu, Xiaohong, Golding, Bernard T., Griffin, Roger J., Hutton, Claire, Newell, David R., Ojo, Stephen, Watson, Anna F., Zaytzev, Andrey, Zhao, Yan, Lunec, John, Hardcastle, Ian R.
Published 2013

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation

by Drummond, Catherine J., Esfandiari, Arman, Liu, Junfeng, Lu, Xiaohong, Hutton, Claire, Jackson, Jennifer, Bennaceur, Karim, Xu, Qing, Makimanejavali, Aditya Rao, Bello, Fabio Del, Piergentili, Alessandro, Newell, David R., Hardcastle, Ian R., Griffin, Roger J., Lunec, John
Published in Oncotarget (2016)

Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer

by Coffey, Kelly, Blackburn, Timothy J., Cook, Susan, Golding, Bernard T., Griffin, Roger J., Hardcastle, Ian R., Hewitt, Lorraine, Huberman, Kety, McNeill, Hesta V., Newell, David R., Roche, Celine, Ryan-Munden, Claudia A., Watson, Anna, Robson, Craig N.
Published 2012

2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase

by Matheson, Christopher J., Coxon, Christopher R., Bayliss, Richard, Boxall, Kathy, Carbain, Benoit, Fry, Andrew M., Hardcastle, Ian R., Harnor, Suzannah J., Mas-Droux, Corine, Newell, David R., Richards, Mark W., Sivaprakasam, Mangaleswaran, Turner, David, Griffin, Roger J., Golding, Bernard T., Cano, Céline
Published in RSC Med Chem (2020)

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

by Johnson, Neil, Li, Yu-Chen, Walton, Zandra E., Cheng, Katherine A., Li, Danan, Rodig, Scott J., Moreau, Lisa A., Unitt, Christine, Bronson, Roderick T., Thomas, Huw D., Newell, David R., D’Andrea, Alan D., Curtin, Nicola J., Wong, Kwok-Kin, Shapiro, Geoffrey I.
Published 2011

Structure-guided design of purine-based probes for selective Nek2 inhibition

by Coxon, Christopher R., Wong, Christopher, Bayliss, Richard, Boxall, Kathy, Carr, Katherine H., Fry, Andrew M., Hardcastle, Ian R., Matheson, Christopher J., Newell, David R., Sivaprakasam, Mangaleswaran, Thomas, Huw, Turner, David, Yeoh, Sharon, Wang, Lan Z., Griffin, Roger J., Golding, Bernard T., Cano, Céline
Published in Oncotarget (2016)